Actelion Acquires CoTherix For $420 mil.
This article was originally published in The Pink Sheet Daily
Executive Summary
Swiss firm projects that sales of its newly acquired product Ventavis could add roughly $100 mil. in 2007 revenue.
You may also be interested in...
Actelion’s Tracleer Hangs On Against Label-Dampened Letairis
Edema risk with Gilead competitor probably a class effect or caused by PAH itself, analyst tells "The Pink Sheet" DAILY.
Actelion’s Tracleer Hangs On Against Label-Dampened Letairis
Edema risk with Gilead competitor probably a class effect or caused by PAH itself, analyst tells "The Pink Sheet" DAILY.
Acusphere Again Delays Imagify NDA, Cites Lengthy Manufacturing Ramp-Up
Firm now targets an early 2008 submission for the cardiac perfusion imaging agent.